Abstract
Group A meningococci are primarily responsible for the epidemic meningococcal diseases in the countries of the meningitis belt of sub-Saharan Africa. In 1995-1996 major epidemics (>200000 cases) impeded effective management and ultimately resulted in many improvements. Since 2003, the Multi-Disease Center (MDSC) in Ouagadougou (Burkina Faso) and the WHO in Geneva have collected epidemiologic and laboratory data; new alert and epidemic thresholds are applied; and management has improved, with a single dose of ceftriaxone or of oily chloramphenicol now recommended. Trivalent ACW vaccine has been introduced against serogroup W135 epidemics. In 2010, preventive vaccination campaigns using the meningococcal conjugate vaccine MenAfriVac(®) began. Their use in all countries of the meningitis belt could eliminate serogroup A outbreaks in the region.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
